Androcur Effects on Quality of Life
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00908674|
Recruitment Status : Completed
First Posted : May 27, 2009
Last Update Posted : April 13, 2010
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Drug: Cyproterone acetate (Androcur)|
|Study Type :||Observational|
|Actual Enrollment :||245 participants|
|Official Title:||Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||January 2010|
Drug: Cyproterone acetate (Androcur)
The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).
Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.
Administration period: 12 months.
- Quality of life change measured by SF-35 questionnaire [ Time Frame: Baseline, after 3, 6 and 12 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908674
|Many Locations, Hungary|
|Study Director:||Bayer Study Director||Bayer|